Table S1: Multivariable Cox-regression analysis (log-rank ratio test, forwards stepwise) of landmark TTP. The factors included were antimetablitecontaining immunosuppression after diagnosis of PTLD, transplanted organ, time from transplant to PTLD, Ann Arbor stage III/IV and elevated LDH at diagnosis.

Landmark TTP		
	Risk factor not in the equation	р
Cox regression model n=110, Block 0, p=0.643	Antimetabolite-containing immunosuppression after diagnosis of PTLD	0.890
	Kidney transplantation	0.367
	Liver transplantation	0.328
	Lung transplantation	0.764
	Heart transplantation	0.252
	Heart/kidney transplantation	0.442
	Pancreas/Kidney transplantation	0.403
	Time from transplant to PTLD	0.185
	Ann Arbor stage III/IV	0.441
	Elevated LDH at diagnosis	0.321

Table S2: Multivariable Cox-regression analysis (log-rank ratio test, forwards stepwise) of landmark TTP. The factors included were: Corticosteroidcontaining immunosuppression after diagnosis of PTLD, age at diagnosis, sex, transplanted organ, time from transplant to PTLD and EBV-association.

Landmark TTP					
	Risk factor	р	Hazard ratio	95% Confidence interval	
Cox regression model n=107, Step 2, p<0.001	Age (years)	<0.001	1.086	1.040 – 1.133	
	Corticosteroid-containing immunosuppression after diagnosis of PTLD	0.001	12.450	2.737 – 56.624	

Variables not in the equation at step 2: sex (p=0.834), transplanted organ (kidney p=0.611, liver p=0.570, lung p=0.746, heart p=0.852, heart/kidney p=0.799, pancreas/kidney p=0.722), time from transplant to PTLD (p=0.685), and EBVassociation (p=0.251).

Figure S1: Landmark analysis of time to progression in patients without evidence of progression 1 year after start of treatment by dose change of CNI at diagnosis of PTLD. A blue line denotes patients stopping the CNI, a green line a reduction to 1-50% of the previous dose, an orange line a reduction to 51-99%, a red line an identical dose and a yellow line a dose increase. **A:** Landmark TTP by dose change of tacrolimus in 55 patients on tacrolimus before diagnosis of PTLD (p=0.797). **B:** Landmark TTP by dose change of ciclosporin in 34 patients on ciclosporin before diagnosis of PTLD (p=0.568).

